Remedium Bio closes $10 million Series A round for a therapy that turns fat cells into protein producers

Remedium Bio closes $10 million Series A round for a therapy that turns fat cells into protein producers

On 10 August, Lifespan Vision Ventures announced the initial close of a $10 million Series A round for Remedium Bio. The funding will support the development of its therapeutic programs, expansion of the technology, and preparations for the first clinical trials in humans.

Protein drugs often require repeated administration because the body gradually clears the supplied molecule. Remedium Bio is developing a system that delivers DNA instructions to subcutaneous fat tissue, enabling its cells to produce the required therapeutic protein themselves.

Such an injection also requires a way to reduce protein production. Prometheus, the company’s system, delivers plasmid DNA to fat cells in lipid nanoparticles. Plasmid DNA is a small circular molecule carrying genetic instructions, while lipid nanoparticles are particles made from fat molecules that transport cargo into cells. In a 2024 study, this construct reached approximately four out of five primary human fat cells in culture. In mice, protein production in the subcutaneous tissue around the injection site continued for six months.

The authors also tested ways to target the cells in this area. In mouse experiments, cryolipolysis, which uses controlled cooling of fat tissue, and focused ultrasound reduced protein production. In another approach, an integrated iCasp9 genetic switch triggered the death of cells containing the DNA after administration of a drug, which also reduced production.

The injection therefore leaves a defined area that can be targeted to reduce protein production.

The published results come from cell culture and mouse experiments. The new funding round will support the transition to the first clinical trials of this system.